Antimicrobial	B:C0427965
susceptibility	I:C0427965
of	O
Pseudomonas	B:C0033809
aeruginosa	I:C0033809
before	O
and	O
after	O
initiation	O
of	O
inhaled	B:C0723764
tobramycin	I:C0723764
in	O
Bulgaria	B:C0006368
.	O

In	O
aim	O
to	O
achieve	O
better	O
infection	B:C0085557
control	I:C0085557
and	O
possible	O
eradication	B:C3178994
of	O
the	O
pathogens	O
involved	O
in	O
chronic	B:C0151317
infections	I:C0151317
of	O
patients	O
with	O
cystic	B:C0010674
fibrosis	I:C0010674
(	O
cystic	B:C0010674
fibrosis	I:C0010674
)	O
scientists	B:C0402112
have	O
developed	O
a	O
new	O
way	O
to	O
administer	O
antimicrobials	B:C0003232
-	O
inhalation	O
.	O

The	O
first	O
and	O
so	O
far	O
the	O
only	O
available	O
inhalable	B:C0004048
antimicrobial	B:C0003232
in	O
Bulgaria	B:C0006368
is	O
inhaled	B:C0723764
tobramycin	I:C0723764
(	O
tobramycin	B:C0723764
)	O
,	O
introduced	O
in	O
2009	O
.	O

We	O
aimed	O
to	O
evaluate	B:C0220825
the	O
antimicrobial	B:C0427965
susceptibility	I:C0427965
of	O
Pseudomonas	B:C0033809
aeruginosa	I:C0033809
isolates	B:C3494793
from	O
cystic	B:C0010674
fibrosis	I:C0010674
(	O
cystic	B:C0010674
fibrosis	I:C0010674
)	O
patients	O
before	O
and	O
after	O
initiation	O
of	O
tobramycin	B:C0723764
in	O
the	O
regular	O
treatment	B:C0040808
regimen	I:C0040808
.	O

We	O
have	O
determined	O
the	O
minimal	B:C0427978
inhibitory	I:C0427978
concentration	I:C0427978
(	O
minimal	B:C0427978
inhibitory	I:C0427978
concentration	I:C0427978
)	O
of	O
17	O
antimicrobials	B:C0003232
by	O
the	O
E-	B:C1275991
test	I:C1275991
(	O
LIOFILCHEM	O
)	O
in	O
sputa	B:C0444159
samples	I:C0444159
of	O
118	O
cystic	B:C0010674
fibrosis	I:C0010674
patients	O
for	O
the	O
period	O
of	O
2005	O
-	O
2014	O
.	O

The	O
results	O
were	O
interpreted	O
according	O
to	O
the	O
annual	B:C0282574
Clinical	I:C0282574
and	I:C0282574
Laboratory	I:C0282574
Standards	I:C0282574
Institute	I:C0282574
guidelines	I:C0282574
.	O

In	O
the	O
sputa	B:C0038056
of	O
70	O
patients	O
a	O
total	O
of	O
102	O
P.	B:C0033809
aeruginosa	I:C0033809
isolates	B:C3494793
were	O
found	O
.	O

Sixty	O
-	O
eight	O
out	O
of	O
102	O
(	O
66.7	O
%	O
)	O
were	O
susceptible	O
to	O
all	O
studied	O
antimicrobials	B:C0003232
.	O

We	O
divided	O
the	O
isolates	B:C3494793
in	O
two	O
chronological	B:C0008717
groups	O
:	O
those	O
collected	O
before	O
the	O
introduction	O
of	O
tobramycin	B:C0723764
as	O
a	O
regular	O
treatment	O
in	O
2009	O
and	O
those	O
collected	O
after	O
2009	O
.	O

A	O
significant	O
reduction	O
(	O
p	O
<	O
0,001	O
-	O
0,02	O
)	O
in	O
susceptibility	O
for	O
the	O
strains	O
after	O
2009	O
was	O
noted	O
towards	O
piperacillin	B:C0031955
(	O
100	O
%	O
vs	O
50	O
%	O
)	O
,	O
ceftazidime	B:C0007559
(	O
100	O
%	O
/	O
77.3	O
%	O
)	O
,	O
cefepime	B:C0055003
(	O
97.9	O
%	O
/	O
68.2	O
%	O
)	O
,	O
amikacin	B:C0002499
(	O
100	O
%	O
/	O
63.6	O
%	O
)	O
,	O
gentamicin	B:C3854019
(	O
95.7	O
%	O
/	O
40.9	O
%	O
)	O
,	O
tobramycin	B:C0040341
(	O
93.6	O
%	O
/	O
59.1	O
%	O
)	O
and	O
ciprofloxacin	B:C0008809
(	O
93.6	O
%	O
/	O
45.5	O
%	O
)	O
.	O

The	O
introduction	O
of	O
inhaled	B:C0723764
tobramycin	I:C0723764
as	O
a	O
regular	O
therapy	B:C0087111
for	O
cystic	B:C0010674
fibrosis	I:C0010674
patients	O
in	O
Bulgaria	B:C0006368
lead	O
to	O
a	O
significant	O
change	O
in	O
antimicrobial	B:C0427965
susceptibility	I:C0427965
of	O
cystic	B:C0010674
fibrosis	I:C0010674
P.	B:C0033809
aeruginosa	I:C0033809
.	O

